VivoSeq
Psychiatry

OCD

0

Pipeline Programs↗

7

Active Trials↗

1

Companies Involved↗

OCD is an early-stage landscape with 0 programs across 1 company. The most active players are Orphatech Pharmaceuticals, GmbH.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Orphatech Pharmaceuticals, GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Recruiting6 · 46%
Unknown status3 · 23%
Completed1 · 8%
Withdrawn1 · 8%
Terminated1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
Recruiting·—·Phase 2·NCT05783817·40 enrolled
Study of Dextromethorphan in OCD and Related Disorders
Recruiting·SStanford University·Phase 2·NCT04899687·60 enrolled
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
Recruiting·YYale University·Phase 1/2·NCT04131829·100 enrolled
Pairing tVNS and Exposure and Response Prevention to Improve Symptoms of OCD
Recruiting·UUniversity of Florida·Preclinical·NCT05580614·56 enrolled
Light Therapy for Obsessive-compulsive Disorder: A Circadian Medicine Approach
Recruiting·WWashington University School of Medicine·Phase 1·NCT06720090·40 enrolled
Harnessing Hormonal Variation to Probe Neural Mechanisms and Optimize CBT Outcomes for OCD
Recruiting·UUniversity of Pennsylvania·Preclinical·NCT05359562·120 enrolled
Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks
Not yet recruiting·BBaylor College of Medicine·N/A·NCT03313622·20 enrolled
PsilOCD: A Pharmacological-Challenge Feasibility Study
Completed·IImperial College London·Phase 1·NCT06258031·19 enrolled
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
Terminated·YYale University·N/A·NCT06624137·5 enrolled
Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A
Withdrawn·OOrphatech Pharmaceuticals, GmbH·Phase 1/2·NCT00957749·10 enrolled
EEG Results of Deep TMS in Patients With OCD
Unknown status·IIstanbul Medipol University Hospital·N/A·NCT05188833·30 enrolled
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
Unknown status·—·N/A·NCT04904952·60 enrolled
Effect of Pyridoxine as Add-on Therapy in OCD Patients
Unknown status·—·N/A·NCT06244121·76 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)